Senior Executive Incentive Package

RNS Number : 8383A

Epistem Holdings plc

26 March 2013

 



Epistem Plc

("Epistem" or "the Company")

Senior Executive Incentive Package

The Board of Epistem (AIM: EHP), the rapidly growing biotechnology company, recognises the importance of incentivising and rewarding the performance of its key executives and has asked the remuneration committee to review the long term incentive plan for its senior executives.

Following the recommendation of the remuneration committee, the Company has today made the following awards to Matthew Walls, CEO:

á       the issue of options over 23,758 ordinary shares of £0.015p, representing 0.25% of the current issued share capital of the Company, exercisable at 550p per share, being the current market value of Epistem's shares and based on the Company's standard performance criteria;

á       an enhanced bonus package related to realised shareholder value, with details to be finalized by the remuneration committee for release in due course.

For further information contact:

Epistem Plc

Matthew Walls, Chief Executive Officer                                        ++44 161 606 7258                         

John Rylands, Chief Financial Officer                                          

Peel Hunt LLP

Nominated Adviser: James Steel/Vijay Barathan                           ++44 207 418 8900                                                                   

Wallbrook PR

Mike Wort/Anna Dunphy                                                 ++44 207 933 8780

Notes for editors

Epistem is a biotechnology and personalised medicine company commercialising its expertise in epithelial stem cells and molecular amplification in the areas of oncology, gastrointestinal, dermatological and infectious disease.                                                                                                                                            

Epistem develops innovative therapeutics, biomarkers and diagnostics alongside providing preclinical services to drug development companies. Epistem's core expertise is focused on the regulation of adult stem cells located in epithelial tissue. Epistem also has a range of proprietary amplification (RNA and DNA) technologies for use in drug discovery, development and diagnostics.

 

END

 

 

RDSLLFEAVDIEFIV